Literature DB >> 30922953

Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.

Yoon-Chul Kye1, Sung-Moo Park2, Byoung-Shik Shim3, Jannatul Firdous1, Girak Kim2, Han Wool Kim1, Young-Jun Ju1, Cheol Gyun Kim1, Chong-Su Cho1, Dong Wook Kim4, Jae Ho Cho5, Man Ki Song6, Seung Hyun Han7, Cheol-Heui Yun8.   

Abstract

Developing effective mucosal subunit vaccine for the Streptococcus pneumoniae has been unsuccessful mainly because of their poor immunogenicity with insufficient memory T and B cell responses. We thus address whether such limitation can be overcome by introducing effective adjuvants that can enhance immunity and show here that polysorbitol transporter (PST) serves as a mucosal adjuvant for a subunit vaccine against the Streptococcus pneumoniae. Pneumococcal surface protein A (PspA) with PST adjuvant induced protective immunity against S. pneumoniae challenge, especially long-term T and B cell immune responses. Moreover, we found that the PST preferentially induced T helper (Th) responses toward Th2 or T follicular helper (Tfh) cells and, importantly, that the responses were mediated through antigen-presenting cells via activating a peroxisome proliferator-activated receptor gamma (PPAR-γ) pathway. Thus, these data indicate that PST can be used as an effective and safe mucosal vaccine adjuvant against S. pneumoniae infection. STATE OF SIGNIFICANCE: In this study, we suggested the nanoparticle forming adjuvant, PST works as an effective adjuvant for the pneumococcal vaccine, PspA. The PspA subunit vaccine together with PST adjuvant efficiently induced protective immunity, even in the long-term memory responses, against Streptococcus pneumoniae lethal challenge. We found that PspA with PST adjuvant induced dendritic cell activation followed by follicular helper T cell responses through PPAR-γ pathway resulting long-term memory antibody-producing cells. Consequently, in this paper, we suggest the mechanism for safe nanoparticle forming subunit vaccine adjuvant against pneumococcal infection.
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Nanoparticle; Pneumococcal surface protein A; Polysorbitol transporter; Streptococcus pneumoniae; Vaccine adjuvant

Mesh:

Substances:

Year:  2019        PMID: 30922953     DOI: 10.1016/j.actbio.2019.03.049

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  7 in total

1.  Efficacy of heads-up CPR compared to supine CPR positions: Systematic review and meta-analysis.

Authors:  Joseph Varney; Karam R Motawea; Mostafa R Mostafa; Yossef H AbdelQadir; Merna Aboelenein; Omneya A Kandil; Nancy Ibrahim; Hashim T Hashim; Kimberly Murry; Garrett Jackson; Jaffer Shah; Maty Boury; Ahmed K Awad; Priya Patel; Dina M Awad; Samah S Rozan; Nesreen E Talat
Journal:  Health Sci Rep       Date:  2022-05-24

2.  Autolysin (lytA) recombinant protein: a potential target for developing vaccines against pneumococcal infections.

Authors:  Davoud Afshar; Farzaneh Rafiee; Mozhgan Kheirandish; Solmaz Ohadian Moghadam; Mohammad Azarsa
Journal:  Clin Exp Vaccine Res       Date:  2020-07-31

3.  Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs.

Authors:  Douglas Borges de Figueiredo; Kan Kaneko; Tasson da Costa Rodrigues; Ronan MacLoughlin; Eliane Namie Miyaji; Imran Saleem; Viviane Maimoni Gonçalves
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

Review 4.  Panel 8: Vaccines and immunology.

Authors:  Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-12-18       Impact factor: 1.675

Review 5.  The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8+ T Cell Responses.

Authors:  Cheol Gyun Kim; Yoon-Chul Kye; Cheol-Heui Yun
Journal:  Pharmaceutics       Date:  2019-11-15       Impact factor: 6.321

Review 6.  PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature.

Authors:  Antoine Fakhry AbdelMassih; Rahma Menshawey; Jumana H Ismail; Reem J Husseiny; Yousef M Husseiny; Shenoda Yacoub; Aya Kamel; Rafeef Hozaien; Elaria Yacoub; Esraa Menshawey; Abanoub Abdelmalek; Ahmed Abouelazaem; Ahmed Elhatw; Ahmed Aboelmaaty; Alaaelrahman Shahib; Amany Mansour; Aya Kamal; Basant Mohamed; Bemen Atif; Beshoy Ghabreal; Catherine Abdelmalak; David Ibrahim; Ebtesam Elsaify; Farah Magdy; Farid G Hanna; Hadeer Hafez; Hafsa Dahir; Kerlos Merhom; Maram Ahmed; Mariam Bishara; Mina Tawfik; Mina Youssef; Mohamed El Sharnouby; Mourad Hamouda; Musheera Ammar; Nada Ali; Nada Daniel; Nadine El-Husseiny; Noha Abdelraouf; Nuran K Abdelhameed; Radwa Ahmed; Radwa Othman; Rahma Mohamadein; Rana Allam; Rana Elgendy; Rana Shebl; Saged Elsherbiney; Sarah Fouad; Sara Emel; Sara Owais; Sarah Hetta; Samah El-Saman; Shaimaa Abdelalim; Sherin Galal; Yara Asar; Yara Osman; Yasmeen Khalaf; Youstina Aziz; Yousra Khafagy; Nervana Gamal; Biagio Castaldi
Journal:  J Genet Eng Biotechnol       Date:  2021-05-31

7.  Nanoparticles to Improve the Efficacy of Vaccines.

Authors:  Cheol-Heui Yun; Chong-Su Cho
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.